%0 Journal Article
%A Frisoni, Giovanni B
%A Hansson, Oskar
%A Nichols, Emma
%A Garibotto, Valentina
%A Schindler, Suzanne E
%A van der Flier, Wiesje M
%A Jessen, Frank
%A Villain, Nicolas
%A Arenaza-Urquijo, Eider M
%A Crivelli, Lucia
%A Fortea, Juan
%A Grinberg, Lea T
%A Ismail, Zahinoor
%A Minoshima, Satoshi
%A Ossenkoppele, Rik
%A Zetterberg, Henrik
%A Petersen, Ronald C
%A Dubois, Bruno
%T New landscape of the diagnosis of Alzheimer's disease.
%J The lancet
%V 406
%N 10510
%@ 0140-6736
%C London [u.a.]
%I Elsevier
%M DZNE-2025-01131
%P 1389 - 1407
%D 2025
%X Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis-a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide.
%K Humans
%K Alzheimer Disease: diagnosis
%K Alzheimer Disease: cerebrospinal fluid
%K Biomarkers: cerebrospinal fluid
%K Biomarkers: blood
%K Amyloid beta-Peptides: metabolism
%K Amyloid beta-Peptides: cerebrospinal fluid
%K tau Proteins: cerebrospinal fluid
%K tau Proteins: metabolism
%K Diagnosis, Differential
%K Positron-Emission Tomography
%K Biomarkers (NLM Chemicals)
%K Amyloid beta-Peptides (NLM Chemicals)
%K tau Proteins (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40997838
%R 10.1016/S0140-6736(25)01294-2
%U https://pub.dzne.de/record/281510